Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review

Conclusions Little clinical difference was found between epoetin SEBs and the reference product. Although not deemed clinically important, the financial implication of a possible dose difference between epoetin zeta and reference product should be considered in pharmacoeconomic studies. Ongoing trials are expected to address the risk of pure-red-cell aplasia with HX 575.
Source: Canadian Journal of Kidney Health and Disease - Category: Urology & Nephrology Source Type: research